179 related articles for article (PubMed ID: 24093636)
1. Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma.
Wang B; Yuan Y; Han L; Ye L; Shi X; Feng M
J Drug Target; 2014 Jan; 22(1):76-85. PubMed ID: 24093636
[TBL] [Abstract][Full Text] [Related]
2. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier.
Yuan Y; Wang W; Wang B; Zhu H; Zhang B; Feng M
J Drug Target; 2013 May; 21(4):367-74. PubMed ID: 23600747
[TBL] [Abstract][Full Text] [Related]
3. Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells.
Garg M; Madan J; Pandey RS; Sardana S; Katyal A; Chandra R
Anticancer Drugs; 2012 Sep; 23(8):836-45. PubMed ID: 22407250
[TBL] [Abstract][Full Text] [Related]
4. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
[TBL] [Abstract][Full Text] [Related]
5. Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer.
Chang JE; Yoon IS; Sun PL; Yi E; Jheon S; Shim CK
J Photochem Photobiol B; 2014 Nov; 140():49-56. PubMed ID: 25090224
[TBL] [Abstract][Full Text] [Related]
6. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
7. Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells.
Villa R; Cerroni B; Viganò L; Margheritelli S; Abolafio G; Oddo L; Paradossi G; Zaffaroni N
Colloids Surf B Biointerfaces; 2013 Oct; 110():434-42. PubMed ID: 23759384
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-loaded Fe
Cheng C; Li C; Zhu X; Han W; Li J; Lv Y
J Biomater Appl; 2019 May; 33(10):1373-1381. PubMed ID: 30880566
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of garcinia glycosides by reconstituted high-density lipoprotein nano-complexes.
Liu C; Zhou Z; Chen Y; Liu J; Wang Y; Liu H
J Microencapsul; 2018 Mar; 35(2):115-120. PubMed ID: 29195484
[TBL] [Abstract][Full Text] [Related]
10. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
[TBL] [Abstract][Full Text] [Related]
11. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect.
Wiradharma N; Tong YW; Yang YY
Biomaterials; 2009 Jun; 30(17):3100-9. PubMed ID: 19342093
[TBL] [Abstract][Full Text] [Related]
12. Theranostics for hepatocellular carcinoma with Fe3O4@ZnO nanocomposites.
Zhang H; Patel N; Ding S; Xiong J; Wu P
Biomater Sci; 2016 Feb; 4(2):288-98. PubMed ID: 26523294
[TBL] [Abstract][Full Text] [Related]
13. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
14. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Li M; Su Y; Zhang F; Chen K; Xu X; Xu L; Zhou J; Wang W
Acta Biomater; 2018 Jul; 75():413-426. PubMed ID: 29859368
[TBL] [Abstract][Full Text] [Related]
15. Collaborative assembly of doxorubicin and galactosyl diblock glycopolymers for targeted drug delivery of hepatocellular carcinoma.
Li J; Zhang Y; Cai C; Rong X; Shao M; Li J; Yang C; Yu G
Biomater Sci; 2020 Jan; 8(1):189-200. PubMed ID: 31821399
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
18. Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin.
Pang Z; Gao H; Yu Y; Guo L; Chen J; Pan S; Ren J; Wen Z; Jiang X
Bioconjug Chem; 2011 Jun; 22(6):1171-80. PubMed ID: 21528923
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines.
Wang J; Chan JY; Fong CC; Tzang CH; Fung KP; Yang M
Liver Int; 2009 Oct; 29(9):1338-47. PubMed ID: 19627484
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
Ye J; Zhang R; Chai W; Du X
Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
